Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.
Nucl Med Biol. 2014 Jan;41(1):102-5. doi: 10.1016/j.nucmedbio.2013.08.008. Epub 2013 Sep 26.
[(11)C]FLB 457, a radioligand with very high affinity and selectivity for dopamine D2/3 receptors, is used to measure receptor binding in extrastriatal regions showing low density of the receptors. The purpose of this study was to estimate the whole-body biodistribution of radioactivity and the radiation absorbed doses to organs after intravenous injection of [(11)C]FLB 457 in healthy human subjects.
Whole-body images were acquired for 2 h after an injection of [(11)C]FLB 457 in six healthy humans. Radiation absorbed doses were estimated by the MIRD scheme implemented in OLINDA/EXM 1.1 software.
Organs with the longest residence time were the liver, lungs, and brain. The organs with the highest radiation doses were the kidneys, liver, and pancreas. The effective dose delivered by [(11)C]FLB 457 is 5.9 μSv/MBq, similar to those of other (11)C-labeled tracers.
This effective dose would allow multiple scans in the same individual based on prevailing maximum recommended-dose guidelines in the USA and Europe.
[(11)C]FLB 457 是一种对多巴胺 D2/3 受体具有极高亲和力和选择性的放射性配体,用于测量受体结合在受体密度较低的外纹状体区域。本研究的目的是估计静脉注射 [(11)C]FLB 457 后健康人体的放射性活度的全身生物分布和器官的辐射吸收剂量。
在 6 名健康志愿者中注射 [(11)C]FLB 457 后 2 小时采集全身图像。通过 OLINDA/EXM 1.1 软件中的 MIRD 方案估算辐射吸收剂量。
滞留时间最长的器官是肝脏、肺和脑。辐射剂量最高的器官是肾脏、肝脏和胰腺。[(11)C]FLB 457 的有效剂量为 5.9 μSv/MBq,与其他 (11)C 标记示踪剂相似。
根据美国和欧洲现行的最大推荐剂量指南,该有效剂量允许在同一患者中进行多次扫描。